Parabilis Medicines
PublicParabilis Medicines is now publicly traded
The data on this page reflects Parabilis Medicines's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Jun 9, 2026
Last Round
Series F
Jan 8, 2026
Total Funding Raised
$1.57B
Company Overview
Parabilis Medicines is a clinical-stage biopharmaceutical company that develops stabilized helical peptide therapeutics, known as Helicons, to target undruggable protein-protein interactions in oncology.
AI Layer
Application
Keywords
Parabilis Medicines Comparables
Compare Parabilis Medicines with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| WntRx Pharmaceuticals | 77% | |
| Sapience Therapeutics | 77% | |
| Circle Pharma | 76% |
For institutional investors. Book with your work email.
Parabilis Medicines Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO | Jun 9, 2026 | ||||
| Series F | Jan 8, 2026 | ||||
| Series E | Mar 1, 2024 | ||||
| Series D | Nov 21, 2022 | ||||
| Series C | Mar 1, 2021 | ||||
Series B | May 16, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Parabilis Medicines Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Soleus Capital | Series F |
| Janus Henderson Group | Series F |
| Horizons Ventures | Series B |
| Boyu Capital | Series B |
| RA Capital Management | Series E, Series F |
| Farallon Capital Management | Series F, Series C, Series E, Series D |
| Sixty Degree Capital | Series F, Series E |
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventOct 24, 2026
Parabilis Medicines presents updated clinical data for zolucatetide in patients with desmoid tumors at the European Society for Medical Oncology (ESMO) Congress 2026 in Spain from Oct 23rd-27th '26.
- attends_eventOct 19, 2026
Parabilis Medicines presents updated clinical data for zolucatetide in patients with desmoid tumors at ESMO Congress 2026 in Spain in Oct '26.
- has_revenueSep 14, 2026
Parabilis Medicines generates $150K in quarterly revenue alongside a $2.32-per-share loss.
- attends_eventSep 1, 2026
Parabilis Medicines is set to participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference in New York on Sep 16th '26.
- is_developingSep 1, 2026
Parabilis Medicines is pursuing a follow-on β-catenin degrader program and advancing additional Helicon-based programs focused on ERG and allosteric ARON in prostate cancer.
For institutional investors. Book with your work email.
Parabilis Medicines Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.